06.03.2017
MorphoSys AG DE0006632003
DGAP-News: MorphoSys Partner to Start New Phase 3 Clinical Trials with Gantenerumab in Alzheimer's Disease
DGAP-News: MorphoSys AG / Key word(s): Study
MorphoSys Partner to Start New Phase 3 Clinical Trials with Gantenerumab in
Alzheimer's Disease (news with additional features)
06.03.2017 / 07:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Planegg/Munich, Germany, March 6, 2017
MorphoSys Partner to Start New Phase 3 Clinical Trials with Gantenerumab in
Alzheimer's Disease
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY)
announced today that its partner Roche plans to initiate a new pivotal
phase 3 program for gantenerumab in patients with prodromal to mild
Alzheimer's disease. Gantenerumab is a monoclonal antibody directed against
beta amyloid generated by MorphoSys using its proprietary HuCAL antibody
technology.
MorphoSys was informed that Roche intends to commence preparations for two
studies and would expect to start the program later this year. Further
information including details of the trials are not yet available.
"This is great news for MorphoSys. We are delighted by the strong
commitment to gantenerumab as a potential new therapy for Alzheimer's
disease", commented Dr. Marlies Sproll, Chief Scientific Officer of
MorphoSys AG. "The HuCAL-derived antibody gantenerumab has properties that
we believe make it a promising candidate to treat Alzheimer's disease, and
we look forward to learning more about these new phase 3 trials".
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology
in the pharmaceutical industry. By successfully applying this and other
patented technologies, MorphoSys has become a leader in the field of
therapeutic antibodies, one of the fastest-growing drug classes in human
healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeutic pipeline of more than 100 human antibody drug candidates for
the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to
name just a few. With its ongoing commitment to new antibody technology and
drug development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys, visit http://
www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R),
Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the
MorphoSys Group.
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies. The forward-looking statements contained
herein represent the judgment of MorphoSys as of the date of this release
and involve risks and uncertainties. Should actual conditions differ from
the Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-
looking statements as far as the wording of the relevant press release is
concerned.
For more information, please contact:
MorphoSys AG
Anke Linnartz
Head of Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Alexandra Goller
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
[email protected]
---------------------------------------------------------------------------
Additional features:
Document: http://n.eqs.com/c/fncls.ssp?u=WKQVJJXSIH
Document title: Media Release
---------------------------------------------------------------------------
06.03.2017 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: [email protected]
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
550267 06.03.2017
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
MorphoSys AG ISIN: DE0006632003 können Sie bei EQS abrufen
Biotechnologie , 663200 , MOR , XETR:MOR